- Home
- PRTA vs ACP Comparison
PRTA vs ACP Comparison
Compare PRTA & ACP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- ACP
- Stock Information
- Founded
- PRTA 2012
- ACP 2010
- Country
- PRTA Ireland
- ACP United States
- Employees
- PRTA N/A
- ACP N/A
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- ACP Investment Managers
- Sector
- PRTA Health Care
- ACP Finance
- Exchange
- PRTA Nasdaq
- ACP Nasdaq
- Market Cap
- PRTA 809.8M
- ACP 744.0M
- IPO Year
- PRTA N/A
- ACP N/A
- Fundamental
- Price
- PRTA $12.14
- ACP $5.87
- Analyst Decision
- PRTA Buy
- ACP
- Analyst Count
- PRTA 9
- ACP 0
- Target Price
- PRTA $54.57
- ACP N/A
- AVG Volume (30 Days)
- PRTA 454.8K
- ACP 337.9K
- Earning Date
- PRTA 05-07-2025
- ACP 01-01-0001
- Dividend Yield
- PRTA N/A
- ACP 17.79%
- EPS Growth
- PRTA N/A
- ACP N/A
- EPS
- PRTA N/A
- ACP N/A
- Revenue
- PRTA $135,157,000.00
- ACP N/A
- Revenue This Year
- PRTA N/A
- ACP N/A
- Revenue Next Year
- PRTA $131.75
- ACP N/A
- P/E Ratio
- PRTA N/A
- ACP N/A
- Revenue Growth
- PRTA 47.92
- ACP N/A
- 52 Week Low
- PRTA $11.42
- ACP $5.55
- 52 Week High
- PRTA $25.42
- ACP $7.17
- Technical
- Relative Strength Index (RSI)
- PRTA 38.46
- ACP 37.10
- Support Level
- PRTA $11.42
- ACP $5.85
- Resistance Level
- PRTA $13.52
- ACP $5.92
- Average True Range (ATR)
- PRTA 0.75
- ACP 0.06
- MACD
- PRTA -0.12
- ACP -0.01
- Stochastic Oscillator
- PRTA 24.66
- ACP 11.90
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
About ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.